ZEPP Fundamental Analysis - ZEPP HEALTH CORP-ADR

Name: ZEPP HEALTH CORP-ADR (ZEPP) Stock
Brand: ZEPP HEALTH CORP-ADR
Rating: 6 (3 reviews)

Fundamental Rating

Overall ZEPP gets a fundamental rating of 2 out of 10. We evaluated ZEPP against 123 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of ZEPP have multiple concerns. ZEPP is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ZEPP had negative earnings in the past year.

The reported net income has been mixed in the past 5 years: ZEPP reported negative net income in multiple years.

In multiple years ZEPP reported negative operating cash flow during the last 5 years.

1.2 Ratios

ZEPP's Return On Assets of -14.18% is on the low side compared to the rest of the industry. ZEPP is outperformed by 67.48% of its industry peers.

Looking at the Return On Equity, with a value of -34.61%, ZEPP is doing worse than 72.36% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-14.18%
ROE	-34.61%
ROIC	N/A

ROA(3y)-8.27%

ROA(5y)-3.78%

ROE(3y)-16.67%

ROE(5y)-7.49%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 37.59%, ZEPP is doing good in the industry, outperforming 62.60% of the companies in the same industry.

In the last couple of years the Gross Margin of ZEPP has grown nicely.

The Profit Margin and Operating Margin are not available for ZEPP so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	37.59%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y22.57%

GM growth 5Y8.78%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ZEPP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ZEPP has less shares outstanding

The number of shares outstanding for ZEPP has been reduced compared to 5 years ago.

The debt/assets ratio for ZEPP is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 4.72 indicates that ZEPP is not in any danger for bankruptcy at the moment.

ZEPP has a better Altman-Z score (4.72) than 65.85% of its industry peers.

A Debt/Equity ratio of 0.85 indicates that ZEPP is somewhat dependend on debt financing.

ZEPP has a Debt to Equity ratio of 0.85. This is amonst the worse of the industry: ZEPP underperforms 87.80% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.85
Debt/FCF	N/A
Altman-Z	4.72

ROIC/WACCN/A

WACC7.06%

2.3 Liquidity

A Current Ratio of 1.10 indicates that ZEPP should not have too much problems paying its short term obligations.

With a Current ratio value of 1.10, ZEPP is not doing good in the industry: 86.99% of the companies in the same industry are doing better.

ZEPP has a Quick Ratio of 1.10. This is a bad value and indicates that ZEPP is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of ZEPP (0.77) is worse than 88.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.1
Quick Ratio	0.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ZEPP have decreased strongly by -172.73% in the last year.

The Revenue for ZEPP has decreased by -18.93% in the past year. This is quite bad

Measured over the past years, ZEPP shows a very negative growth in Revenue. The Revenue has been decreasing by -26.33% on average per year.

EPS 1Y (TTM)-172.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%25%

Revenue 1Y (TTM)-18.93%

Revenue growth 3Y-42.67%

Revenue growth 5Y-26.33%

Sales Q2Q%46.18%

3.2 Future

ZEPP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.82% yearly.

ZEPP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.50% yearly.

EPS Next Y43.41%

EPS Next 2Y32.82%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year37.49%

Revenue Next 2Y31.5%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZEPP. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZEPP. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ZEPP's earnings are expected to grow with 32.82% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.82%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ZEPP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ZEPP HEALTH CORP-ADR

NYSE:ZEPP (10/27/2025, 8:04:00 PM)

After market: 46 0 (0%)

+4.84 (+11.76%)

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupTechnology Hardware & Equipment

GICS IndustryElectronic Equipment, Instruments & Components

Earnings (Last)08-03 2025-08-03/bmo

Earnings (Next)11-04 2025-11-04

Inst Owners29.96%

Inst Owner Change-24.98%

Ins Owners5.91%

Ins Owner ChangeN/A

Market Cap2.76B

Revenue(TTM)200.00M

Net Income(TTM)-77867000

Analysts82.86

Price Target61.43 (33.54%)

Short Float %9.14%

Short Ratio1.75

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)388.88%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-51.08%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)4.03%

Revenue NY rev (3m)15.31%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	13.8
P/FCF	N/A
P/OCF	N/A
P/B	12.26
P/tB	13.7
EV/EBITDA	N/A

EPS(TTM)-8.57

EYN/A

EPS(NY)-0.37

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS3.33

BVpS3.75

TBVpS3.36

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.18%
ROE	-34.61%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	37.59%
FCFM	N/A

ROA(3y)-8.27%

ROA(5y)-3.78%

ROE(3y)-16.67%

ROE(5y)-7.49%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y22.57%

GM growth 5Y8.78%

F-ScoreN/A

Asset Turnover0.36

Health

		Industry Rank	Sector Rank
Debt/Equity	0.85
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.1
Quick Ratio	0.77
Altman-Z	4.72

F-ScoreN/A

WACC7.06%

ROIC/WACCN/A

Cap/Depr(3y)22.81%

Cap/Depr(5y)96.65%

Cap/Sales(3y)0.51%

Cap/Sales(5y)0.74%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-172.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%25%

EPS Next Y43.41%

EPS Next 2Y32.82%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-18.93%

Revenue growth 3Y-42.67%

Revenue growth 5Y-26.33%

Sales Q2Q%46.18%

Revenue Next Year37.49%

Revenue Next 2Y31.5%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-91.73%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year49.29%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-162.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-156.9%

OCF growth 3YN/A

OCF growth 5YN/A

ZEPP HEALTH CORP-ADR / ZEPP FAQ

What is the fundamental rating for ZEPP stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZEPP.

Can you provide the valuation status for ZEPP HEALTH CORP-ADR?

ChartMill assigns a valuation rating of 1 / 10 to ZEPP HEALTH CORP-ADR (ZEPP). This can be considered as Overvalued.

Can you provide the profitability details for ZEPP HEALTH CORP-ADR?

ZEPP HEALTH CORP-ADR (ZEPP) has a profitability rating of 2 / 10.

ZEPP HEALTH CORP-ADR (ZEPP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ZEPP HEALTH CORP-ADR / ZEPP FAQ

What is the fundamental rating for ZEPP stock?

Can you provide the valuation status for ZEPP HEALTH CORP-ADR?

Can you provide the profitability details for ZEPP HEALTH CORP-ADR?